{ "schemaVersion": 1, "organisationId": "O-47ed936d747646518f5d4791c59f6c2e", "slug": "moderna-inc", "name": "Moderna, Inc.", "updatedAt": "2026-10-02T10:58:25.803155Z", "sections": [ { "type": "OVERVIEW", "text": "Moderna, Inc. is a biotechnology company that develops mRNA medicines, applying its platform to vaccines and investigational therapies. Its commercial portfolio includes COVID-19 vaccines Spikevax and mNEXSPIKE and the RSV vaccine mRESVIA; its pipeline spans infectious diseases, oncology and rare diseases. [P3089172][https://www.modernatx.com/power-of-mrna/modernas-mrna-platform][https://www.modernatx.com/products] Moderna states its mission is “to deliver the greatest possible impact to people through mRNA medicines.” [https://www.modernatx.com/about-us/our-mission]\n\nThe company sells internationally, with the United States its largest market, and reported approximately 4,700 full-time employees across 18 countries at the end of 2025. [P104121059][P88312505] For the year ended December 31, 2025, Moderna reported total revenue of $1.944 billion. [T119272]\n[P3089172][P104121059][P88312505][T119272][https://www.modernatx.com/power-of-mrna/modernas-mrna-platform][https://www.modernatx.com/products][https://www.modernatx.com/about-us/our-mission]", "updatedAt": "2026-10-02T10:58:25.803155Z" }, { "type": "PRODUCTS", "text": "Moderna’s marketed vaccine products include Spikevax and mNEXSPIKE for COVID-19, and mRESVIA for respiratory syncytial virus (RSV). The 2025–26 versions of Spikevax and mNEXSPIKE target SARS-CoV-2 variant LP.8.1. mNEXSPIKE is approved for adults 65 and older and for high-risk people aged 12–64; its mRNA dose is one-fifth that of Spikevax. Spikevax is approved in the United States for high-risk people aged 6 months–64 and all adults 65 and older. [P48986552][P34396256] mRESVIA encodes an engineered RSV F protein stabilized in its prefusion conformation and uses Moderna’s lipid nanoparticle formulation. It is approved for adults 60 and older, with approvals also covering higher-risk adults aged 18–59 in some markets. [P60201618]\n\nmCOMBRIAX (mRNA-1083) is a combination vaccine for influenza and COVID-19 that received European Commission authorization for people aged 50 and older in April 2026; it had not been commercialized by June 30, 2026. It combines the antigens used in Moderna’s seasonal influenza candidate mRNA-1010 and its COVID-19 vaccine mNEXSPIKE. [P145405464][P34847619] Other candidates include mRNA-1010, a seasonal influenza vaccine encoding hemagglutinin strains recommended by the World Health Organization, and mRNA-3927, an investigational therapy for propionic acidemia. [P69591781][P64165096][P145405300] Intismeran autogene is another investigational product, being studied in oncology trials with Merck. [P78045595]\n\nThe company’s technical capabilities include mRNA design and controls intended to direct or limit translation in selected tissues, as well as manufacturing mRNA drug substance and product from research and early clinical stages through Phase 3 and commercial production. [P79299316][P19881396][P118136803] Its filings also describe collaboration and manufacturing-related revenue, rather than a separately defined general-purpose services portfolio. [P145405514]\n\nModerna reported $1.818 billion in net product sales for 2025, down 42% from 2024, primarily reflecting lower COVID-19 vaccine volumes. [P460643][P104121059] In the first half of 2026, product-type sales were $446 million: $436 million from COVID-19 products and $10 million from RSV, equivalent to approximately 97.8% and 2.2%, respectively. The filing groups COVID-19 sales rather than disclosing a separate Spikevax and mNEXSPIKE split. [T16633016][P145405280]\n[P48986552][P34396256][P60201618][P145405464][P34847619][P69591781][P64165096][P145405300][P78045595][P79299316][P19881396][P118136803][P145405514][P460643][P104121059][T16633016][T16633016][P145405280]", "updatedAt": "2026-10-02T10:58:25.803155Z" }, { "type": "GEOGRAPHY", "text": "For FY2025, Moderna identified the United States as its largest market and described sales across the U.S., Europe, and the rest of the world. It reported no revenue breakdown by country or region; FY2025 total revenue was $1.944 billion, including $1.818 billion in net product sales, company-wide figures rather than geographic splits. [P3089172][P104121059][T119272]\n\nThe company’s principal corporate office and headquarters are in Cambridge, Massachusetts, and it also has a main campus in Norwood, Massachusetts. Its U.S. footprint includes a large Norwood lab and office campus and a biomanufacturing facility in Marlborough, Massachusetts, which became operational in August 2025. [P116748373][P51835260][P73263708][P32340177]\n\nOutside the U.S., Moderna’s manufacturing network includes company-owned facilities in Laval, Quebec; Clayton, Victoria, Australia; and Harwell, Oxfordshire, UK. The company reported these sites were licensed in 2025 and associated with multi-year government purchase commitments; its Canada vaccine fill-and-finish is performed by Novocol Pharma in Cambridge, Ontario. Moderna had approximately 4,700 full-time employees in 18 countries as of December 31, 2025, without a country-level headcount breakdown in the cited disclosure. [P16914117][P51337284][P84895832][P110333238][P106502778][P88312505]\n[P3089172][P104121059][T119272][P116748373][P51835260][P73263708][P32340177][P16914117][P51337284][P84895832][P110333238][P106502778][P88312505]", "updatedAt": "2026-10-02T10:58:25.803155Z" }, { "type": "SEGMENTS", "text": "Moderna reports one operating and reportable segment, focused on researching, developing, and commercializing medicines based on messenger RNA (mRNA). The company’s chief operating decision maker assesses performance and allocates resources on a consolidated basis; accordingly, this single segment represents 100% of reported 2025 revenue, or $1.944 billion. [P77096179][T119272]\n\nModerna does not report product or geographic categories as separate operating segments. For additional revenue context, 2025 net product sales were $1.818 billion (approximately 93.5% of revenue) and other revenue was $126 million (approximately 6.5%); these are revenue categories, not segments. The company also reported approximately $1.2 billion in U.S. revenue and $745 million internationally, rounded figures that equate to roughly 61.7% and 38.3% of total revenue, respectively. [T119272][P100468974]\n\nThe latest available 2026 filing is interim: for the six months ended June 30, 2026, Moderna reported $534 million of revenue, comprising $446 million in net product sales (approximately 83.5%) and $88 million in other revenue (approximately 16.5%). These categories likewise do not represent separate segments. [P145405208]\n[P77096179][T119272][P100468974][P145405208]", "updatedAt": "2026-10-02T10:58:25.803155Z" }, { "type": "HISTORY", "text": "Moderna traces its founding to 2010, with Noubar Afeyan, Robert Langer and Derrick Rossi among its founders; Stéphane Bancel joined as founding CEO in 2011. Its legal predecessor was incorporated in 2009, became Moderna Therapeutics, LLC in 2013, and adopted the name Moderna, Inc. in August 2018. [https://www.modernatx.com/about-us/our-story][https://news.modernatx.com/news/news-details/2012/moderna-announces-40-million-in-financing-to-advance-development-of-new-biotherapeutic-modality-messenger-rna-therapeutics][P116748373]\n\nThe company marked its first human dose of an mRNA vaccine in 2015. In December 2018, it completed its initial public offering and began trading on Nasdaq. Moderna started developing its COVID-19 vaccine in January 2020; it received U.S. emergency authorization in December 2020 and FDA approval as SPIKEVAX in January 2022. [https://www.modernatx.com/about-us/our-story][https://www.sec.gov/Archives/edgar/data/1682852/000119312518344982/d611137d424b4.htm][https://news.modernatx.com/news/news-details/2023/leveraging-13-years-of-investment-in-mrna-innovation-for-future-pandemic-preparedness][https://www.fda.gov/vaccines-blood-biologics/spikevax]\n\nIn 2023, Moderna acquired Japan-based OriCiro Genomics, adding its capabilities to the company’s mRNA technology platform. In 2024, the FDA approved mRESVIA, Moderna’s vaccine against respiratory syncytial virus (RSV). [https://www.modernatx.com/media-center/all-media/blogs/moderna-2023-shareholder-letter][https://www.modernatx.com/media-center/all-media/blogs/introducing-worlds-first-rsv-mrna-vaccine]\n[P116748373][https://www.modernatx.com/about-us/our-story][https://news.modernatx.com/news/news-details/2012/moderna-announces-40-million-in-financing-to-advance-development-of-new-biotherapeutic-modality-messenger-rna-therapeutics][https://www.sec.gov/Archives/edgar/data/1682852/000119312518344982/d611137d424b4.htm][https://news.modernatx.com/news/news-details/2023/leveraging-13-years-of-investment-in-mrna-innovation-for-future-pandemic-preparedness][https://www.fda.gov/vaccines-blood-biologics/spikevax][https://www.modernatx.com/media-center/all-media/blogs/moderna-2023-shareholder-letter][https://www.modernatx.com/media-center/all-media/blogs/introducing-worlds-first-rsv-mrna-vaccine]", "updatedAt": "2026-10-02T10:58:25.803155Z" } ], "sources": [ { "id": "P3089172", "href": "https://app.finbar.com/go?id=P3089172", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "https://www.modernatx.com/power-of-mrna/modernas-mrna-platform", "href": "https://www.modernatx.com/power-of-mrna/modernas-mrna-platform", "label": "www.modernatx.com" }, { "id": "https://www.modernatx.com/products", "href": "https://www.modernatx.com/products", "label": "www.modernatx.com" }, { "id": "https://www.modernatx.com/about-us/our-mission", "href": "https://www.modernatx.com/about-us/our-mission", "label": "www.modernatx.com" }, { "id": "P104121059", "href": "https://app.finbar.com/go?id=P104121059", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P88312505", "href": "https://app.finbar.com/go?id=P88312505", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "T119272", "href": "https://app.finbar.com/go?id=T119272", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P48986552", "href": "https://app.finbar.com/go?id=P48986552", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P34396256", "href": "https://app.finbar.com/go?id=P34396256", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P60201618", "href": "https://app.finbar.com/go?id=P60201618", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P145405464", "href": "https://app.finbar.com/go?id=P145405464", "label": "Moderna, Inc. — Full financial report (2026 Q 2)", "documentId": "D-a3b9f45684fc407a8471ef6896da5d17" }, { "id": "P34847619", "href": "https://app.finbar.com/go?id=P34847619", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P69591781", "href": "https://app.finbar.com/go?id=P69591781", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P64165096", "href": "https://app.finbar.com/go?id=P64165096", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P145405300", "href": "https://app.finbar.com/go?id=P145405300", "label": "Moderna, Inc. — Full financial report (2026 Q 2)", "documentId": "D-a3b9f45684fc407a8471ef6896da5d17" }, { "id": "P78045595", "href": "https://app.finbar.com/go?id=P78045595", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P79299316", "href": "https://app.finbar.com/go?id=P79299316", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P19881396", "href": "https://app.finbar.com/go?id=P19881396", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P118136803", "href": "https://app.finbar.com/go?id=P118136803", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P145405514", "href": "https://app.finbar.com/go?id=P145405514", "label": "Moderna, Inc. — Full financial report (2026 Q 2)", "documentId": "D-a3b9f45684fc407a8471ef6896da5d17" }, { "id": "P460643", "href": "https://app.finbar.com/go?id=P460643", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "T16633016", "href": "https://app.finbar.com/go?id=T16633016", "label": "Moderna, Inc. — Full financial report (2026 Q 2)", "documentId": "D-a3b9f45684fc407a8471ef6896da5d17" }, { "id": "P145405280", "href": "https://app.finbar.com/go?id=P145405280", "label": "Moderna, Inc. — Full financial report (2026 Q 2)", "documentId": "D-a3b9f45684fc407a8471ef6896da5d17" }, { "id": "P116748373", "href": "https://app.finbar.com/go?id=P116748373", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P51835260", "href": "https://app.finbar.com/go?id=P51835260", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P73263708", "href": "https://app.finbar.com/go?id=P73263708", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P32340177", "href": "https://app.finbar.com/go?id=P32340177", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P16914117", "href": "https://app.finbar.com/go?id=P16914117", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P51337284", "href": "https://app.finbar.com/go?id=P51337284", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P84895832", "href": "https://app.finbar.com/go?id=P84895832", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P110333238", "href": "https://app.finbar.com/go?id=P110333238", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P106502778", "href": "https://app.finbar.com/go?id=P106502778", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P77096179", "href": "https://app.finbar.com/go?id=P77096179", "label": "Moderna, Inc. — Full financial report (2025 Y)", "documentId": "D-48143a490bd34738adbb9ac4296d51ba" }, { "id": "P100468974", "href": "https://app.finbar.com/go?id=P100468974", "label": "Moderna, Inc. — Press release (2025 Y)", "documentId": "D-9b1a807c221a4fd2bababb56f4c62fc5" }, { "id": "P145405208", "href": "https://app.finbar.com/go?id=P145405208", "label": "Moderna, Inc. — Full financial report (2026 Q 2)", "documentId": "D-a3b9f45684fc407a8471ef6896da5d17" }, { "id": "https://www.modernatx.com/about-us/our-story", "href": "https://www.modernatx.com/about-us/our-story", "label": "www.modernatx.com" }, { "id": "https://news.modernatx.com/news/news-details/2012/moderna-announces-40-million-in-financing-to-advance-development-of-new-biotherapeutic-modality-messenger-rna-therapeutics", "href": "https://news.modernatx.com/news/news-details/2012/moderna-announces-40-million-in-financing-to-advance-development-of-new-biotherapeutic-modality-messenger-rna-therapeutics", "label": "news.modernatx.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1682852/000119312518344982/d611137d424b4.htm", "href": "https://www.sec.gov/Archives/edgar/data/1682852/000119312518344982/d611137d424b4.htm", "label": "www.sec.gov" }, { "id": "https://news.modernatx.com/news/news-details/2023/leveraging-13-years-of-investment-in-mrna-innovation-for-future-pandemic-preparedness", "href": "https://news.modernatx.com/news/news-details/2023/leveraging-13-years-of-investment-in-mrna-innovation-for-future-pandemic-preparedness", "label": "news.modernatx.com" }, { "id": "https://www.fda.gov/vaccines-blood-biologics/spikevax", "href": "https://www.fda.gov/vaccines-blood-biologics/spikevax", "label": "www.fda.gov" }, { "id": "https://www.modernatx.com/media-center/all-media/blogs/moderna-2023-shareholder-letter", "href": "https://www.modernatx.com/media-center/all-media/blogs/moderna-2023-shareholder-letter", "label": "www.modernatx.com" }, { "id": "https://www.modernatx.com/media-center/all-media/blogs/introducing-worlds-first-rsv-mrna-vaccine", "href": "https://www.modernatx.com/media-center/all-media/blogs/introducing-worlds-first-rsv-mrna-vaccine", "label": "www.modernatx.com" } ] }